Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 57 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area LymphomaStatus unknownNCT04860674Phase 2
• A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid TumorsStatus unknownNCT04859777Phase 1
• Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Phase 3
• First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsActive, not recruitingNCT04858269Phase 2
• SBRT + Atezolizumab + Bevacizumab in Resectable HCCActive, not recruitingNCT04857684Early Phase 1
• A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell CancerCompletedNCT04856631Phase 1/2
• A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyTerminatedNCT04856176Phase 2
• Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell CarcinomaStatus unknownNCT04851132Not applicable
• Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTTStatus unknownNCT04850157Phase 2
• A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and OxaliplatinStatus unknownNCT04850040Phase 2
• PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUPStatus unknownNCT04848597Phase 2
• Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant TherapyStatus unknownNCT04848454Phase 2
• Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck CaActive, not recruitingNCT04848116Phase 2
• A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04845139Not applicable
• Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCCStatus unknownNCT04843943Phase 1/2
• cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven CriteriaCompletedNCT04842565Phase 2
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AMLStatus unknownNCT04842370Phase 1
• A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic TumorsWithdrawnNCT04841538Phase 1/2
• Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingNCT04841148Phase 2
• Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung CancerStatus unknownNCT04840758Phase 1/2
• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsSuspendedNCT04840589Phase 1
• BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)CompletedNCT04839471Phase 2
• Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerActive, not recruitingNCT04837209Phase 2
• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingNCT04835805Phase 1
• Electroporation Potentiated Immunotherapy in CancerActive, not recruitingNCT04835402Phase 2
• A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanomaTerminatedNCT04834973Phase 1/2
• PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal CancerActive, not recruitingNCT04833387Phase 2
• Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver MetastasesStatus unknownNCT04832204Phase 2
• Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
• Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT04831450Phase 2
• Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorActive, not recruitingNCT04831320Phase 2
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedNCT04830124Phase 2
• Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung CancerStatus unknownNCT04828395Phase 2
• RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose RadiotherapyCompletedNCT04827862Phase 2
• ASP8374 + Cemiplimab in Recurrent GliomaCompletedNCT04826393Phase 1
• Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal CancerActive, not recruitingNCT04825990Phase 2
• A Phase Ib Study of HX008 in Patients With Advanced Solid TumorsStatus unknownNCT04825392Phase 1
• Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal CancerCompletedNCT04821765Phase 2
• TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingNCT04817826Phase 2
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT04815720Phase 1/2
• A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL StudyStatus unknownNCT04814069Phase 2
• PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814043Phase 2
• Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814030Phase 2
• Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ AdenocarcinomaStatus unknownNCT04813523Phase 2
• Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04813406Not applicable
• Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedNCT04810611Phase 1
• PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBCStatus unknownNCT04809779Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary CancerStatus unknownNCT04809142Phase 3
• Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid TumorsWithdrawnNCT04809012Phase 2
• A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated GliomasActive, not recruitingNCT04808245Phase 1
• A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical CancerWithdrawnNCT04806945Phase 3
• Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast CancerCompletedNCT04805736Phase 2
• Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell CarcinomaTerminatedNCT04804696Phase 2
• SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaActive, not recruitingNCT04803877Phase 2
• Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic CancerStatus unknownNCT04803851Phase 1/2
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerWithdrawnNCT04799431Phase 1
• Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)CompletedNCT04799353Phase 1
• SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell CancerStatus unknownNCT04797507Phase 2
• Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCLStatus unknownNCT04796857Phase 1/2
• Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
• Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.Active, not recruitingNCT04795661Phase 2
• A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic MalignancyCompletedNCT04795128Phase 1
• Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)CompletedNCT04793815Not applicable
• Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell CarcinomaActive, not recruitingNCT04792073Phase 2
• Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerActive, not recruitingNCT04791839Phase 2
• a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung CancerStatus unknownNCT04790539Phase 2
• Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsCompletedNCT04790409Phase 2
• Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2
• Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedNCT04787991Phase 1
• Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid MalignanciesTerminatedNCT04785287Phase 1/2
• Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue SarcomaActive, not recruitingNCT04784247Phase 2
• Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative RecurrenceStatus unknownNCT04782804Phase 1/2
• Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
• The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract CancersActive, not recruitingNCT04781192Phase 1/2
• Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and DostarlimabTerminatedNCT04779151Phase 2
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7TerminatedNCT04777851Phase 3
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver CancerTerminatedNCT04777708Early Phase 1
• Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal CancerStatus unknownNCT04777162Phase 2
• Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnNCT04776876Phase 2
• Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal CancerActive, not recruitingNCT04776590Phase 2
• A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesCompletedNCT04772989Phase 1
• A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Phase 3
• Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2
• Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLCCompletedNCT04768075Phase 3
• A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT04767295Phase 2
• Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCTerminatedNCT04765709Phase 2
• Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid MalignancyCompletedNCT04763616Phase 2
• A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid CancersStatus unknownNCT04761744Phase 2
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingNCT04759586Phase 3
• Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast CancerActive, not recruitingNCT04759248Phase 2
• FL-101 in Surgically Resectable Non-Small Cell Lung CancerWithdrawnNCT04758949Phase 2
• A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerActive, not recruitingNCT04757363Phase 2
• A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced MelanomaStatus unknownNCT04756934Phase 1
• A Study of LP002 for the Treatment of Patients With Malignant Digestive System NeoplasmsStatus unknownNCT04755543Phase 1
• Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Active, not recruitingNCT04753879Phase 2
• Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerActive, not recruitingNCT04751370Phase 2
• A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast CancerStatus unknownNCT04750382Phase 1/2

← Immune Checkpoint Inhibitors overview